STEPHANIE GILES: Open Payments
NPI 1750539771 · FREEHOLD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,522 in 59 payments from 20 companies in 2025. Trend: 2023 $1,530 · 2024 $1,966 · 2025 $1,522
Food & beverage: $1,522
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $493 |
| Genentech USA, Inc. | 11 | $158 |
| Regeneron Healthcare Solutions, Inc. | 8 | $140 |
| CSL Behring | 6 | $137 |
| GENZYME CORPORATION | 1 | $129 |
| GlaxoSmithKline, LLC. | 5 | $81 |
| Janssen Biotech, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Novartis Pharmaceuticals Corporation | 2 | $36 |
| BioCryst US Sales Co., LLC | 2 | $35 |
Products named: TEZSPIRE, DUPIXENT, FASENRA, XOLAIR, Hizentra, TRELEGY ELLIPTA, TREMFYA, ORLADEYO.
Industry payments across NJ — which companies pay providers there.
